

Brazil Vaccine Market Growth Analysis Report - Market Size, Share, Forecast Trends and Outlook (2025-2034)

Market Report | 2025-06-20 | 250 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2789.00
- Five User License \$3909.00
- Corporate License \$5099.00

Report description:

The Brazil vaccine market was valued at USD 3.92 Billion in 2024 , driven by the surge in infectious disease cases and rising public-private partnerships in the region. The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034, with the values likely to reach USD 7.09 Billion by 2034 . The market is propelled by the growing public health infrastructure and high vaccination acceptance rates. Expanding adult vaccination programs and advancements in mRNA vaccine technologies are expected to fuel demand in the forecast period.

Brazil Vaccine Market Overview

A vaccine is a biological substance designed to stimulate the body's immune response against one or more specific diseases. It trains the immune system to recognize and combat pathogens, such as viruses or bacteria, by introducing harmless components or inactivated forms of the pathogen. This helps prevent future infections and supports public health through immunization. The market is expanding due to rising government immunization programs, increased awareness, and growing demand for COVID-19 and influenza vaccines, supported by both domestic production and international pharmaceutical collaborations.

Brazil Vaccine Market Growth Drivers

Surge in Dengue Cases to Drive Market Demand

The sharp rise in dengue fever cases is emerging as a significant growth driver for the market. According to data from the Brazilian Health Ministry, in February 2024, Brazil reported 262,247 dengue cases in the first four weeks, which is four times the number of cases recorded during the same period in 2023, creating an urgent demand for vaccination. This public health crisis, coupled with increasing vaccination demand, is set to substantially accelerate growth in the vaccine market in Brazil.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Brazil Vaccine Market Trends

Some of the notable trends in the market are the large-scale dengue vaccination initiative and robust collaboration between the federal government and the private sector:

Mass Dengue Vaccination Campaign to Boost the Market Growth

A notable trend in the market is the growing adoption of mass vaccination campaigns, driven by rising dengue cases. In January 2024, the city of Dourados launched the country's first large-scale dengue vaccination initiative, targeting 150,000 individuals aged 4 to 59. This strategic push is expected to enhance market growth, with increased demand for dengue vaccines in response to ongoing public health concerns.

Rising Partnerships to Enhance Brazil Vaccine Market Value

A growing trend in the market is the strong collaboration between the federal government and the private sector. This was highlighted by the launch of the Novo PAC program in August 2023, which earmarks investments in health infrastructure, including vaccine production and distribution. With BRL 31 billion allocated to health initiatives, this strategic partnership is expected to significantly boost the vaccine market, ensuring better access and distribution nationwide.

Brazil Vaccine Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

- Multivalent Vaccines
- Monovalent Vaccines

Market Breakup by Type

- Subunit Vaccines
- ??- Recombinant vaccines
- ??- Conjugate Vaccines
- ??- Toxoid vaccines

- Inactivated
- Live Attenuated
- mRNA vaccines
- Viral vector vaccines

Market Breakup by Route of Administration

- Oral
- Parenteral
- Nasal

Market Breakup by Disease Indication

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Viral Diseases
- ??- Hepatitis
- ??- Influenza
- ??- HPV
- ??- MMR
- ??- Rotavirus
- ??- Herpes Zoster
- ??- Covid-19
- ??- Others

- Bacterial Vaccines
- ??- Meningococcal Diseases
- ??- Pneumococcal diseases
- ??- DPT
- ??- Others

- Cancer Vaccines
- Allergy Vaccines

Market Breakup by Age

- Pediatric
- Adult

Market Breakup by End User

- Hospital Pharmacies
- Retail Pharmacies
- Government Suppliers
- Others

Brazil Vaccine Market Share

The Viral Disease Segment Holds a Substantial Market Share

Based on the disease indication, the market is divided into viral diseases, bacterial vaccines, cancer vaccines, and allergy vaccines. Among these, viral diseases are expected to lead the vaccine market due to the ongoing global focus on infectious diseases such as influenza, COVID-19, and dengue. The growing demand for vaccines targeting these viruses, combined with advancements in vaccine technology, is anticipated to elevate the market value.

Brazil Vaccine Market Analysis by Region

The southeast region, including states like Sao Paulo and Minas Gerais, leads the Brazil vaccine market due to its high population density and advanced healthcare infrastructure. The south and central-west regions also show strong growth, driven by improved immunization programs and rising healthcare investments. These regions collectively account for the majority of vaccine demand and distribution.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Leading Players in the Brazil Vaccine Market

The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

GlaxoSmithKline plc

GSK plc, founded in 2000 and headquartered in Brentford, UK, is a global leader in healthcare and vaccines. The company plays a significant role in the Brazil vaccine market with its RSV vaccine, Arexvy, which is available in over 60 countries. At the International RSV Symposium in March 2024, GSK presented pivotal research on Arexvy, emphasizing its immunogenicity, safety, and efficacy, especially for older adults and immunocompromised individuals, addressing the growing demand for RSV vaccines in Brazil.

Merck & Co

Merck & Co., Inc., established in 1891, is a global leader in healthcare. The company, also known as MSD outside the United States and Canada, develops and manufactures vaccines for various diseases, including dengue, influenza, and COVID-19. Merck's global vaccination efforts, such as collaborations with Gavi, enhance vaccine access and confidence, supporting Brazil's vaccination initiatives in response to rising dengue cases.

Pfizer Inc

Pfizer is a key player in the market, producing a wide range of vaccines and medicines. It was established in 1849 and is headquartered in New York. In collaboration with Gavi, Pfizer has made significant contributions to vaccination efforts, including its pneumococcal conjugate vaccines. These vaccines, crucial for preventing pneumonia in children, support immunization initiatives, especially in vulnerable populations, and align with the country's broader health equity goals.

AstraZeneca plc

AstraZeneca plc, established in 1999, is headquartered in Cambridge, United Kingdom. In the Brazil vaccine market, AstraZeneca plays a crucial role with its COVID-19 vaccine, developed in partnership with the University of Oxford. Approved for emergency use in January 2021, the AstraZeneca vaccine has been integral to Brazil's national vaccination efforts during the pandemic.

Other key players in the market include Sanofi, Johnson & Johnson Services, Inc., and CSL Behring.

Key Questions Answered in the Brazil Vaccine Market Report

- What was the Brazil vaccine market value in 2024?
- What is the Brazil vaccine market forecast outlook for 2025-2034?
- What is the market segmentation based on product type?
- What is the market segmentation based on type?
- What is the market breakup based on the route of administration?
- How is the market segmented based on disease indication?
- How is the market divided based on age?
- How is the market divided based on the end user?
- What are the major factors aiding the Brazil vaccine market demand?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major Brazil Vaccine market trends?
- Which product type is expected to dominate the market segment?
- Which type is projected to lead the market segment?
- Which route of administration is projected to lead the market segment?
- Which disease indication is projected to lead the market segment?
- Which age is anticipated to drive the market segment?
- Which end user is likely to dominate the market segment?
- Who are the key players involved in the Brazil vaccine market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

More Insights On

Vaccine Market

Saudi Arabia Vaccine Market

Japan Vaccine Market

Mexico Vaccine Market

Vietnam Vaccine Market

Latin America Vaccine Market

Asia Pacific Vaccine Market

United States Vaccine Market

India Vaccine Market

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Vaccine Market Overview
 - 3.1 Latin America Vaccine Market Overview
 - 3.1.1 Latin America Vaccine Market Historical Value (2018-2024)
 - 3.1.2 Latin America Vaccine Market Forecast Value (2025-2034)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3.2 Brazil Vaccine Market Overview
 - 3.2.1 Brazil Vaccine Market Historical Value (2018-2024)
 - 3.2.2 Brazil Vaccine Market Forecast Value (2025-2034)
- 4 Brazil Vaccine Market Landscape*
 - 4.1 Brazil Vaccine Market: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Brazil Vaccine Market: Product Landscape
 - 4.2.1 Analysis by Product Type
 - 4.2.2 Analysis by Type
 - 4.2.3 Analysis by Route of Administration
 - 4.2.4 Analysis by Disease Indication
 - 4.2.5 Analysis by Age
- 5 Brazil Vaccine Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 PESTEL Analysis
 - 5.3.1 Political
 - 5.3.2 Economic
 - 5.3.3 Social
 - 5.3.4 Technological
 - 5.3.5 Legal
 - 5.3.6 Environment
 - 5.4 Porter's Five Forces Model
 - 5.4.1 Bargaining Power of Suppliers
 - 5.4.2 Bargaining Power of Buyers
 - 5.4.3 Threat of New Entrants
 - 5.4.4 Threat of Substitutes
 - 5.4.5 Degree of Rivalry
 - 5.5 Key Demand Indicators
 - 5.6 Key Price Indicators
 - 5.7 Industry Events, Initiatives, and Trends
 - 5.8 Value Chain Analysis
- 6 Brazil Vaccine Market Segmentation (218-2034)
 - 6.1 Brazil Vaccine Market (2018-2034) by Product Type
 - 6.1.1 Market Overview
 - 6.1.2 Multivalent Vaccines
 - 6.1.3 Monovalent Vaccines
 - 6.2 Brazil Vaccine Market (2018-2034) by Type
 - 6.2.1 Market Overview
 - 6.2.2 Subunit Vaccines
 - 6.2.2.1 Recombinant vaccines

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2.2.2 Conjugate Vaccines
- 6.2.2.3 Toxoid vaccines
- 6.2.3 Inactivated
- 6.2.4 Live Attenuated
- 6.2.5 mRNA vaccines
- 6.2.6 Viral vector vaccines
- 6.3 Brazil Vaccine Market (2018-2034) by Route of Administration
 - 6.3.1 Market Overview
 - 6.3.2 Oral
 - 6.3.3 Parenteral
 - 6.3.4 Nasal
- 6.4 Brazil Vaccine Market (2018-2034) by Disease Indication
 - 6.4.1 Market Overview
 - 6.4.2 Viral Diseases
 - 6.4.2.1 Hepatitis
 - 6.4.2.2 Influenza
 - 6.4.2.3 HPV
 - 6.4.2.4 MMR
 - 6.4.2.5 Rotavirus
 - 6.4.2.6 Herpes Zoster
 - 6.4.2.7 Covid-19
 - 6.4.2.8 Others
 - 6.4.3 Bacterial Vaccines
 - 6.4.3.1 Meningococcal Diseases
 - 6.4.3.2 Pneumococcal diseases
 - 6.4.3.3 DPT
 - 6.4.3.4 Others
 - 6.4.4 Cancer Vaccines
 - 6.4.5 Allergy Vaccines
- 6.5 Brazil Vaccine Market (2018-2034) by Age
 - 6.5.1 Market Overview
 - 6.5.2 Pediatric
 - 6.5.3 Adult
- 6.6 Brazil Vaccine Market (2018-2034) by End User
 - 6.6.1 Market Overview
 - 6.6.2 Hospital Pharmacies
 - 6.6.3 Retail Pharmacies
 - 6.6.4 Government Suppliers
 - 6.6.5 Others
- 7 Regulatory Framework
- 8 Patent Analysis
 - 8.1 Analysis By Drug Type of Patent
 - 8.2 Analysis by Publication Year
 - 8.3 Analysis by Issuing Authority
 - 8.4 Analysis by Patent Age
 - 8.5 Analysis by CPC Analysis
 - 8.6 Analysis by Patent Valuation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.7 Analysis by Key Players
- 9 Clinical Trials Analysis
 - 9.1 Analysis by Trial Registration Year
 - 9.2 Analysis by Trial Status
 - 9.3 Analysis by Trial Phase
 - 9.4 Analysis by Therapeutic Area
 - 9.5 Analysis by Geography
- 10 Funding and Investment Analysis
 - 10.1 Analysis by Funding Instances
 - 10.2 Analysis by Drug Class of Funding
 - 10.3 Analysis by Funding Amount
 - 10.4 Analysis by Leading Players
 - 10.5 Analysis by Leading Investors
 - 10.6 Analysis by Geography
- 11 Strategic Initiatives
 - 11.1 Analysis by Partnership Instances
 - 11.2 Analysis by Drug Class of Partnership
 - 11.3 Analysis by Leading Players
 - 11.4 Analysis by Geography
- 12 Supplier Landscape
 - 12.1 GlaxoSmithKline plc
 - 12.1.1 Financial Analysis
 - 12.1.2 Product Portfolio
 - 12.1.3 Demographic Reach and Achievements
 - 12.1.4 Company News and Development
 - 12.1.5 Certifications
 - 12.2 Merck & Co.
 - 12.2.1 Financial Analysis
 - 12.2.2 Product Portfolio
 - 12.2.3 Demographic Reach and Achievements
 - 12.2.4 Company News and Development
 - 12.2.5 Certifications
 - 12.3 Sanofi
 - 12.3.1 Financial Analysis
 - 12.3.2 Product Portfolio
 - 12.3.3 Demographic Reach and Achievements
 - 12.3.4 Company News and Development
 - 12.3.5 Certifications
 - 12.4 Pfizer Inc.
 - 12.4.1 Financial Analysis
 - 12.4.2 Product Portfolio
 - 12.4.3 Demographic Reach and Achievements
 - 12.4.4 Company News and Development
 - 12.4.5 Certifications
 - 12.5 AstraZeneca plc
 - 12.5.1 Financial Analysis
 - 12.5.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.5.3 Demographic Reach and Achievements
- 12.5.4 Company News and Development
- 12.5.5 Certifications
- 12.6 Johnson & Johnson Services, Inc.
- 12.6.1 Financial Analysis
- 12.6.2 Product Portfolio
- 12.6.3 Demographic Reach and Achievements
- 12.6.4 Company News and Development
- 12.6.5 Certifications
- 12.7 CSL Behring
- 12.7.1 Financial Analysis
- 12.7.2 Product Portfolio
- 12.7.3 Demographic Reach and Achievements
- 12.7.4 Company News and Development
- 12.7.5 Certifications
- 13 Brazil Vaccine Market - Distribution Model (Additional Insight)
- 13.1 Overview
- 13.2 Potential Distributors
- 13.3 Key Parameters for Distribution Partner Assessment
- 14 Key Opinion Leaders (KOL) Insights (Additional Insight)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Brazil Vaccine Market Growth Analysis Report - Market Size, Share, Forecast Trends and Outlook (2025-2034)

Market Report | 2025-06-20 | 250 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2789.00
	Five User License	\$3909.00
	Corporate License	\$5099.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-23"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

